Natera, Inc. $NTRA Stake Cut by Samlyn Capital LLC

Key Points

• Samlyn Capital LLC has reduced its stake in Natera, Inc. by 49.2%, now holding approximately 235,572 shares worth about $33.31 million.
• Natera reported a quarterly earnings loss of ($0.74) per share, missing analysts' expectations, despite revenue significantly increasing by 32.2% year-over-year to $546.6 million.
• Analyst ratings for Natera are predominantly positive, with the stock currently holding an average rating of "Buy" and a target price of around $194.00.

Samlyn Capital LLC lowered its stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 49.2% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 235,572 shares of the medical research company's stock after selling 227,784 shares during the quarter. Samlyn Capital LLC owned approximately 0.17% of Natera worth $33,312,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in NTRA. LRI Investments LLC acquired a new position in Natera during the 4th quarter worth $29,000. Bank of Jackson Hole Trust bought a new position in shares of Natera in the first quarter worth $29,000. Rakuten Securities Inc. grew its stake in shares of Natera by 117.8% in the first quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock worth $31,000 after purchasing an additional 119 shares in the last quarter. TCTC Holdings LLC grew its stake in shares of Natera by 114.8% in the first quarter. TCTC Holdings LLC now owns 232 shares of the medical research company's stock worth $33,000 after purchasing an additional 124 shares in the last quarter. Finally, ORG Partners LLC bought a new position in shares of Natera in the first quarter worth $32,000. Institutional investors and hedge funds own 99.90% of the company's stock.

Wall Street Analysts Forecast Growth

NTRA has been the subject of several recent analyst reports. Morgan Stanley reissued an "overweight" rating and issued a $195.00 price target on shares of Natera in a research note on Sunday, August 10th. Cowen reissued a "buy" rating on shares of Natera in a research note on Friday, August 8th. Stephens reissued an "overweight" rating and issued a $183.00 price target on shares of Natera in a research note on Friday, August 15th. Royal Bank Of Canada set a $268.00 price target on Natera and gave the stock an "outperform" rating in a research note on Tuesday, September 2nd. Finally, Barclays reissued an "overweight" rating and issued a $210.00 price target (up previously from $190.00) on shares of Natera in a research note on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating and seventeen have assigned a Buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $194.00.

Natera Price Performance

Shares of Natera stock traded up $8.98 during trading on Tuesday, hitting $176.37. The stock had a trading volume of 1,296,953 shares, compared to its average volume of 1,001,568. The firm has a market cap of $24.21 billion, a P/E ratio of -92.34 and a beta of 1.68. The business has a fifty day moving average of $154.63 and a two-hundred day moving average of $153.87. Natera, Inc. has a fifty-two week low of $114.62 and a fifty-two week high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.14). Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The company had revenue of $546.60 million for the quarter, compared to analysts' expectations of $476.84 million. During the same period in the prior year, the company earned ($0.30) earnings per share. The company's revenue for the quarter was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. As a group, research analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current year.

Insider Buying and Selling at Natera

In other news, insider Solomon Moshkevich sold 3,000 shares of the firm's stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $166.62, for a total value of $499,860.00. Following the completion of the sale, the insider owned 120,859 shares of the company's stock, valued at $20,137,526.58. This trade represents a 2.42% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Gail Boxer Marcus sold 2,496 shares of the firm's stock in a transaction on Friday, August 1st. The stock was sold at an average price of $133.17, for a total value of $332,392.32. Following the completion of the sale, the director directly owned 5,763 shares of the company's stock, valued at approximately $767,458.71. This trade represents a 30.22% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 56,423 shares of company stock valued at $8,459,656 over the last 90 days. 5.63% of the stock is owned by insiders.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.